Baidu
map

西安出台意见稿 实现24小时处方审核和药品供应

2018-07-30 张毅伟 三秦都市报

西安食药监出台相关意见,对需要长期使用固定处方药物控制和治疗慢性病的患者,药店可以不重复索取处方只做处方药销售登记。

昨天,记者从西安市食药监局获悉,西安出台相关意见,创新药品零售服务新模式,对需要长期使用固定处方药物控制和治疗慢性病的患者,药店可以不重复索取处方只做处方药销售登记。
推进药品经营企业 多业态经营

西安食药监局出台《关于促进药品流通行业转型升级创新发展的若干意见》,鼓励药品批发企业开办、收购、兼并、重组药品零售连锁企业,实施批发和零售连锁总部储运主体融合,充分利用有效仓储资源和配送服务渠道。鼓励药品零售连锁企业收购、兼并、重组其他药品零售(连锁)企业,支持单体药店加入零售连锁企业。实施统一法人、统一字号、统一采购、统一配送、统一票据、统一质量、统一计算机管理等“七统一”的药品零售连锁企业。

实现24小时处方审核和药品供应

推广“网订店取”“网订店送”等新兴配送方式。支持药品零售企业在行业协会领导下推行电子处方共享平台服务、首营企业和首营品种共享数据库和驻店执业药师远程药学服务,在充分实施驻店药师电子化身份标签的前提下实现24小时处方审核和药品供应。鼓励第三方搭建联通慢性病患者档案系统、医院系统、医生、社区药店、驻店药师、配送系统等的信息服务平台,方便患者自主选择平台内合作药店购药。引导平台设置一键投诉功能,直接连通12345市民服务热线,方便及时解决质量、服务和价格纠纷。

创新药品零售服务新模式

对需要长期使用固定处方药物控制和治疗慢性病的患者,零售药店在完善慢性病患者的诊疗和用药档案的基础上,记录患者既往用药情况、需购买药品的资料以及购买者详细信息,可以不重复索取处方只做处方药销售登记。

推行简政利企便民新举措

以满足群众安全便捷用药的需求为中心,药品批发企业可凭企事业单位介绍信和药品研发机构的申请,向企事业单位销售用于职工防暑降温、防寒防冻防疫、扶贫捐助以及药品研发机构所需的非处方药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725281, encodeId=adae1e25281b6, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Mon Jan 28 17:36:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716331, encodeId=ead71e16331e4, content=<a href='/topic/show?id=c0a18e35889' target=_blank style='color:#2F92EE;'>#药品供应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87358, encryptionId=c0a18e35889, topicName=药品供应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c5232213503, createdName=yyanpro@32cn.c, createdTime=Mon May 06 05:36:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554054, encodeId=dcbb155405448, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Wed Aug 01 11:36:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335251, encodeId=b393335251a7, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 31 07:19:58 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335247, encodeId=c3a633524e09, content=一个很好的尝试,希望可以很好的取长补短, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Jul 31 07:04:54 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335176, encodeId=55213351e649, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 30 21:07:44 CST 2018, time=2018-07-30, status=1, ipAttribution=)]
    2019-01-28 chengjn
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725281, encodeId=adae1e25281b6, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Mon Jan 28 17:36:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716331, encodeId=ead71e16331e4, content=<a href='/topic/show?id=c0a18e35889' target=_blank style='color:#2F92EE;'>#药品供应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87358, encryptionId=c0a18e35889, topicName=药品供应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c5232213503, createdName=yyanpro@32cn.c, createdTime=Mon May 06 05:36:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554054, encodeId=dcbb155405448, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Wed Aug 01 11:36:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335251, encodeId=b393335251a7, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 31 07:19:58 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335247, encodeId=c3a633524e09, content=一个很好的尝试,希望可以很好的取长补短, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Jul 31 07:04:54 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335176, encodeId=55213351e649, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 30 21:07:44 CST 2018, time=2018-07-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725281, encodeId=adae1e25281b6, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Mon Jan 28 17:36:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716331, encodeId=ead71e16331e4, content=<a href='/topic/show?id=c0a18e35889' target=_blank style='color:#2F92EE;'>#药品供应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87358, encryptionId=c0a18e35889, topicName=药品供应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c5232213503, createdName=yyanpro@32cn.c, createdTime=Mon May 06 05:36:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554054, encodeId=dcbb155405448, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Wed Aug 01 11:36:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335251, encodeId=b393335251a7, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 31 07:19:58 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335247, encodeId=c3a633524e09, content=一个很好的尝试,希望可以很好的取长补短, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Jul 31 07:04:54 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335176, encodeId=55213351e649, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 30 21:07:44 CST 2018, time=2018-07-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725281, encodeId=adae1e25281b6, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Mon Jan 28 17:36:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716331, encodeId=ead71e16331e4, content=<a href='/topic/show?id=c0a18e35889' target=_blank style='color:#2F92EE;'>#药品供应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87358, encryptionId=c0a18e35889, topicName=药品供应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c5232213503, createdName=yyanpro@32cn.c, createdTime=Mon May 06 05:36:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554054, encodeId=dcbb155405448, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Wed Aug 01 11:36:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335251, encodeId=b393335251a7, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 31 07:19:58 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335247, encodeId=c3a633524e09, content=一个很好的尝试,希望可以很好的取长补短, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Jul 31 07:04:54 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335176, encodeId=55213351e649, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 30 21:07:44 CST 2018, time=2018-07-30, status=1, ipAttribution=)]
    2018-07-31 明崖

    学习了,有用的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1725281, encodeId=adae1e25281b6, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Mon Jan 28 17:36:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716331, encodeId=ead71e16331e4, content=<a href='/topic/show?id=c0a18e35889' target=_blank style='color:#2F92EE;'>#药品供应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87358, encryptionId=c0a18e35889, topicName=药品供应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c5232213503, createdName=yyanpro@32cn.c, createdTime=Mon May 06 05:36:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554054, encodeId=dcbb155405448, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Wed Aug 01 11:36:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335251, encodeId=b393335251a7, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 31 07:19:58 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335247, encodeId=c3a633524e09, content=一个很好的尝试,希望可以很好的取长补短, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Jul 31 07:04:54 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335176, encodeId=55213351e649, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 30 21:07:44 CST 2018, time=2018-07-30, status=1, ipAttribution=)]
    2018-07-31 太阳系小猪

    一个很好的尝试,希望可以很好的取长补短

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1725281, encodeId=adae1e25281b6, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Mon Jan 28 17:36:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716331, encodeId=ead71e16331e4, content=<a href='/topic/show?id=c0a18e35889' target=_blank style='color:#2F92EE;'>#药品供应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87358, encryptionId=c0a18e35889, topicName=药品供应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c5232213503, createdName=yyanpro@32cn.c, createdTime=Mon May 06 05:36:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554054, encodeId=dcbb155405448, content=<a href='/topic/show?id=e5214241875' target=_blank style='color:#2F92EE;'>#处方审核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42418, encryptionId=e5214241875, topicName=处方审核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c114492745, createdName=chg126, createdTime=Wed Aug 01 11:36:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335251, encodeId=b393335251a7, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 31 07:19:58 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335247, encodeId=c3a633524e09, content=一个很好的尝试,希望可以很好的取长补短, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Jul 31 07:04:54 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335176, encodeId=55213351e649, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 30 21:07:44 CST 2018, time=2018-07-30, status=1, ipAttribution=)]
    2018-07-30 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

大调查:你怎么处理过期药品?

家庭过期药品已被明确列入《国家危险废物名录》,但长期以来,家庭过期药品一直都没有专门的回收和处理渠道,很多人都是直接扔掉。广药集团发布的《中国家庭过期药品回收白皮书》披露,我国80%以上的家庭没有定期清理药箱的习惯,全国一年产生家庭过期药品约1.5万吨。

321药品,不用招标,直接进医院

321药品,不用招标、直接挂网,医院可以采购了。

重大利好!药品从申报到实验,最多60天

临床试验申请默许制正式落地!在我国申报药物临床试验的,自申请受理并缴费之日起60日内,申请人未收到国家食品药品监督管理总局药品审评中心(以下简称药审中心)否定或质疑意见的,可按照提交的方案开展药物临床试验。

中国药品审评审批用时进一步压缩,创新药物审评审批再提速

记者6日从全国药品监管工作座谈会上获悉,我国药品审评审批用时进一步压缩,待审评的药品注册申请已由2015年高峰时的2.2万件降至3200件以内。创新药物和医疗器械审评审批进一步加快,截至今年6月底,共对29批597件药品注册申请进行优先审评审批,审核批准了39个创新医疗器械和4个优先审批医疗器械产品。国家药品监督管理局局长焦红介绍,今年以来,通过持续深化药品医疗器械审评审批制度改革,境外新药上市明

国家医保局开会了!传递重要信号

开会!先传达了国务院对药品集采的要求;另外,医保局改变当前的招标采购模式,准备个试点。

积极应对 我国药品审评审批用时进一步压缩

记者6日从全国药品监管工作座谈会上获悉,我国药品审评审批用时进一步压缩,待审评的药品注册申请已由2015年高峰时的2.2万件降至3200件以内。创新药物和医疗器械审评审批进一步加快,截至今年6月底,共对29批597件药品注册申请进行优先审评审批,审核批准了39个创新医疗器械和4个优先审批医疗器械产品。国家药品监督管理局局长焦红介绍,今年以来,通过持续深化药品医疗器械审评审批制度改革,境外新药上市

Baidu
map
Baidu
map
Baidu
map